ArticleDiscover oncology2026
Characterization of tumour microenvironment in thymic epithelial tumours of different histological subtypes.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThymic epithelial tumours (TETs) include several World Health Organization (WHO) defined histological subtypes, ranging from indolent thymomas to highly aggressive thymic carcinoma (TC). The characteristics of the tumour microenvironment (TME), including immune and metabolic profiles, and their prognostic implications across subtypes remain poorly defined.
methodsWe analyzed tissue samples from 111 patients with TET treated at Sun Yat-sen University Cancer Center (SYSUCC) and transcriptome and single nucleotide polymorphism data from 119 patients in The Cancer Genome Atlas (TCGA). Mutation tree analysis was performed to delineate genetic relationships among the six WHO subtypes. Immune cell infiltration was assessed using CIBERSORT, and amino acid, fatty acid, glucose metabolic activities were quantified with gene set variation analysis. Candidate immunometabolic biomarkers for malignant subtypes were validated by immunohistochemistry in the SYSUCC cohort.
resultsThe mutation tree demonstrated clear genetic divergence among TET subtypes. TC and type B3 thymomas were the most genetically distinct, in keeping with their higher malignant potential and poorer prognosis, whereas type A and AB thymomas clustered together, consistent with their indolent behavior. TME profiling identified three clusters: type A and type AB, type B1 and type B2, and type B3 and TC. Patients with TC or type B3 thymoma exhibited increased macrophage infiltration, enhanced amino acid and fatty acid metabolism, and reduced resting dendritic cells. Immunohistochemistry confirmed overexpression of CD68, GLS2, and ARG2 in aggressive subtypes.
conclusionsThis integrative analysis highlights evolutionary divergence and TME heterogeneity across TET subtypes and identifies immunometabolic biomarkers that may support prognostic assessment and future personalised treatment stratification in aggressive TETs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.